XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells

Teng,Xue; Fan,Xiao‑Fan; Li,Qi; Liu,Shuang; Wu,Dong‑Yuan; Wang,Shu‑Ya; Shi,Yuanqi; Dong,Mei

doi:10.3892/or.2019.6959

XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells

Authors:
- Xue Teng
- Xiao‑Fan Fan
- Qi Li
- Shuang Liu
- Dong‑Yuan Wu
- Shu‑Ya Wang
- Yuanqi Shi
- Mei Dong
View Affiliations

Affiliations: Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150086, P.R. China, Department of Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150086, P.R. China, Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China
Published online on: January 9, 2019 https://doi.org/10.3892/or.2019.6959
Pages: 1875-1882

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Xeroderma pigmentosum, complementation group C (XPC) is an accessory recognition gene involved in the nucleotide excision repair (NER) pathway, which is activated during the initial DNA damage recognition stage. It participates in the regulation of DNA damage‑induced proliferation and apoptosis. Emerging evidence demonstrates that upregulation of XPC increases the resistance of several tumor cell types to cytotoxic drugs. In addition, it can predict poor patient outcome for non‑small cell lung cancer (NSCLC). However, the mechanisms linking upregulation of XPC and drug resistance in lung cancer are still unclear. In the present study, we aimed to confirm whether XPC was involved in the reversal of the cisplatin (DDP) resistance in drug‑resistant A549/DDP lung adenocarcinoma cells. RT‑PCR and western blot assays were used to examine XPC mRNA and protein expression levels. Cell viability was assessed by CCK‑8 assay. The knockdown of XPC was achieved in A549/DDP cells using si‑RNA, whereas cell proliferation and apoptosis were assessed by wound healing assay and ﬂow cytometric analysis, respectively. The median inhibitory concentration (IC50) value of DDP was assessed by CCK‑8 assay. Western blot assays were conducted for the examination of caspase‑9/3, Bax and Bcl‑2 protein levels, whereas the activation of the PI3K/Akt/mTOR signaling pathway was investigated in XPC‑knockdown cells. High expression of XPC was noted in A549/DDP cells compared with that in A549 cells, which was associated with DDP resistance. XPC silencing significantly inhibited A549/DDP cell proliferation and increased the induction of apoptosis. In addition, XPC knockdown decreased the expression levels of the Akt/mTOR signaling proteins and the expression of their downstream mediator. The data of the present study revealed that XPC inhibition rescued DDP resistance in lung adenocarcinoma cells, which was dependent on the Akt/mTOR signaling pathway. Collectively, XPC may be considered a new strategy for curing DDP‑resistant lung cancer and may improve the efficacy of conventional chemotherapy.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	NSCLC Meta-Analyses Collaborative Group: Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 26:4617–4625. 2008. View Article : Google Scholar : PubMed/NCBI
3	Siddik ZH: Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
4	Amable L: Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 106:27–36. 2016. View Article : Google Scholar : PubMed/NCBI
5	Milane L, Ganesh S, Shah S, Duan ZF and Amiji M: Multi-modal strategies for overcoming tumor drug resistance: Hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology. J Control Release. 155:237–247. 2011. View Article : Google Scholar : PubMed/NCBI
6	De Silva IU, McHugh PJ, Clingen PH and Hartley JA: Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol. 20:7980–7990. 2000. View Article : Google Scholar : PubMed/NCBI
7	Shell SM, Hawkins EK, Tsai MS, Hlaing AS, Rizzo CJ and Chazin WJ: Xeroderma pigmentosum complementation group C protein (XPC) serves as a general sensor of damaged DNA. DNA Repair (Amst). 12:947–953. 2013. View Article : Google Scholar : PubMed/NCBI
8	Fautrel A, Andrieux L, Musso O, Boudjema K, Guillouzo A and Langouët S: Overexpression of the two nucleotide excision repair genes ERCC1 and XPC in human hepatocellular carcinoma. J Hepatol. 43:288–293. 2005. View Article : Google Scholar : PubMed/NCBI
9	Yang LC, Hsiao YP, Lu CT, Huang CH, Chao WR, Lin YT, Su HA, Chang SL and Chung JG: Xeroderma pigmentosum complementation group C Protein (XPC) expression in basal cell carcinoma. In Vivo. 29:35–38. 2015.PubMed/NCBI
10	Zhang Y, Yu JJ, Tian Y, Li ZZ, Zhang CY, Zhang SF, Cao LQ, Zhang Y, Qian CY, Zhang W, et al: eIF3a improve cisplatin sensitivity in ovarian cancer by regulating XPC and p27^Kip1 translation. Oncotarget. 6:25441–25451. 2015.PubMed/NCBI
11	Zhang Y, Cao J, Meng Y, Qu C, Shen F and Xu L: Overexpression of xeroderma pigmentosum group C decreases the chemotherapeutic sensitivity of colorectal carcinoma cells to cisplatin. Oncol Lett. 15:6336–6344. 2018.PubMed/NCBI
12	Wang C, Nie H and Li Y, Liu G, Wang X, Xing S, Zhang L, Chen X, Chen Y and Li Y: The study of the relation of DNA repair pathway genes SNPs and the sensitivity to radiotherapy and chemotherapy of NSCLC. Sci Rep. 6:265262016. View Article : Google Scholar : PubMed/NCBI
13	Hollander MC, Philburn RT, Patterson AD, Velasco-Miguel S, Friedberg EC, Linnoila RI and Fornace AJ Jr: Deletion of XPC leads to lung tumors in mice and is associated with early events in human lung carcinogenesis. Proc Natl Acad Sci USA. 102:13200–13205. 2005. View Article : Google Scholar : PubMed/NCBI
14	Wu YH, Wu TC, Liao JW, Yeh KT, Chen CY and Lee H: p53 dysfunction by xeroderma pigmentosum group C defects enhance lung adenocarcinoma metastasis via increased MMP1 expression. Cancer Res. 70:10422–10432. 2010. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Jordheim LP, Crosperrial E, Matera EL, Bouledrak K and Dumontet C: Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability. Clin Exp Pharmacol Physiol. 41:817–824. 2014. View Article : Google Scholar : PubMed/NCBI
17	Du P, Zhang X, Liu H and Chen L: Lentivirus-mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line. DNA Cell Biol. 34:497–502. 2015. View Article : Google Scholar : PubMed/NCBI
18	Wang Z, Liang X, Cheng Z, Xu Y, Yin P, Zhu H, Li Q, Qian X and Liu J: Induction of apoptosis and suppression of ERCC1 expression by the potent amonafide analogue 8-c in human colorectal carcinoma cells. Anticancer Drugs. 24:355–365. 2013. View Article : Google Scholar : PubMed/NCBI
19	Wang W, Zhang L, Liu L, Zheng Y, Zhang Y, Yang S, Shi R and Wang S: Chemosensitizing effect of shRNA-mediated ERCC1 silencing on a Xuanwei lung adenocarcinoma cell line and its clinical significance. Oncol Rep. 37:1989–1997. 2017. View Article : Google Scholar : PubMed/NCBI
20	Despras E, Pfeiffer P, Salles B, Calsou P, Kuhfittig-Kulle S, Angulo JF and Biard DS: Long-term XPC silencing reduces DNA double-strand break repair. Cancer Res. 67:2526–2534. 2007. View Article : Google Scholar : PubMed/NCBI
21	Lai TC, Chow KC, Fang HY, Cho HC, Chen CY, Lin TY, Chiang IP and Ho SP: Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients. Oncol Rep. 25:1243–1251. 2011.PubMed/NCBI
22	Zhang K, Wang X and Wang H: Effect and mechanism of Src tyrosine kinase inhibitor sunitinib on the drug-resistance reversal of human A549/DDP cisplatin-resistant lung cancer cell line. Mol Med Rep. 10:2065–2072. 2014. View Article : Google Scholar : PubMed/NCBI
23	Zhou D, Liu W, Liang S, Sun B, Liu A, Cui Z, Han X and Yuan L: Apoptin-derived peptide reverses cisplatin resistance in gastric cancer through the PI3K-AKT signaling pathway. Cancer Med. 7:1369–1383. 2018. View Article : Google Scholar : PubMed/NCBI
24	Rezvani HR, Kim AL, Rossignol R, Ali N, Daly M, Mahfouf W, Bellance N, Taïeb A, de Verneuil H, Mazurier F and Bickers DR: XPC silencing in normal human keratinocytes triggers metabolic alterations that drive the formation of squamous cell carcinomas. J Clin Invest. 121:195–211. 2011. View Article : Google Scholar : PubMed/NCBI
25	Jiang W, Cheng Y, Zhao N, Li L, Shi Y, Zong A and Wang F: Sulfated polysaccharide of Sepiella Maindroni ink inhibits the migration, invasion and matrix metalloproteinase-2 expression through suppressing EGFR-mediated p38/MAPK and PI3K/Akt/mTOR signaling pathways in SKOV-3 cells. Int J Biol Macromol. 107:349–362. 2018. View Article : Google Scholar : PubMed/NCBI
26	Zhao M, Xu P, Liu Z, Zhen Y, Chen Y, Liu Y, Fu Q, Deng X, Liang Z, Li Y, et al: Dual roles of miR-374a by modulated c-Jun respectively targets CCND1-inducing PI3K/AKT signal and PTEN-suppressing Wnt/β-catenin signaling in non-small-cell lung cancer. Cell Death Dis. 9:782018. View Article : Google Scholar : PubMed/NCBI
27	Cheng H, Zou Y, Ross JS, Wang K, Liu X, Halmos B, Ali SM, Liu H, Verma A, Montagna C, et al: RICTOR amplification defines a novel subset of lung cancer patients who may benefit from treatment with mTOR1/2 inhibitors. Cancer Discov. 5:1262–1270. 2015. View Article : Google Scholar : PubMed/NCBI